AACR 2024

doc1021-phase-i-results

Apr 10, 2024

DOC1021 – Unveiling Hope: Diakonos Oncology’s Breakthrough in Glioblastoma Treatment: AACR 2024

phase-i-ii-trial-of-copanlisib

Apr 10, 2024

Phase I/II trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)

obx-115-phase-i-trial-result

Apr 10, 2024

OBX-115 – TIL Cell Therapy Advancements for ICI-Resistant Advanced Melanoma: AACR 2024

tg4050-phase-i-trial

Apr 10, 2024

Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV-negative head and neck cancers

alx-oncology-evorpacept-combo

Apr 10, 2024

ALX Oncology’s Evorpacept Combo Shows Strong Response in Relapsed B-NHL Patients: AACR 2024

azd1390-for-glioblastoma

Apr 10, 2024

Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM)

alectinib-promising-efficacy-and-tolerability

Apr 10, 2024

Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study

nbf-006-promising-results

Apr 10, 2024

First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer

Delveinsight

Apr 09, 2024

KRYSTAL-1: A pooled phase 1/2 efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRASG12C mutation

ctx130-for-advanced-clear-cell-renal-cell-carcinoma

Apr 09, 2024

CTX130 – CAR T Cell Therapy Offers New Hope for Advanced Clear Cell Renal Cell Carcinoma: AACR 2024

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper